|Awarded On||June 18, 2010|
|Title||Recruitment of First-Time, Tenure-Track Faculty Members|
|Award Mechanism||Recruitment of First-Time, Tenure-Track Faculty Members|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Lauren Ehrlich|
|Cancer Sites||Leukemia, Multiple Sites|
T cell acute lymphoblastic leukemia (T-ALL) arises from developing T cells, occurs predominantly in children and adolescents, and represents ~15% of pediatric ALL cases. The use of intensified chemotherapy regimens has improved the 5-year event free survival to 75-83%. However, non-responding patients have poor outcomes.
Since the central nervous system is frequently a site of relapse, T-ALL patients often receive cranial irradiation, resulting in adverse effects such as impaired cognitive development and secondary tumors. Therefore, development of targeted therapies resulting in less short-term toxicity, a higher percentage of clinical response, and reduced long-term morbidity, would addres...